博雅生物: 公司第八届监事会第十一次会议决议公告

Group 1 - The company held its 11th meeting of the 8th Supervisory Board on July 17, 2025, which was conducted via both in-person and remote voting methods [1][2] - The Supervisory Board approved the company's participation in the establishment of the second phase of the China Resources Pharmaceutical Industry Investment Fund, stating that the transaction aligns with the company's overall strategic planning and is fair and reasonable [1][2] - The Supervisory Board concluded that the transaction would not have a significant adverse impact on the company's cash flow or operating performance, nor would it affect the company's independence or harm the interests of the company and its shareholders [1]